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OBJECTIVE: To analyze the relationship between comorbid
conditions and direct treatment costs for patients diagnosed with
migraine in the Taiwan’s National Health Insurance (NHI)
system. METHODS: Retrospective analyses on continuously
enrolled Individuals diagnosed as having migraine from July 1,
2000 to December 31, 2002 (with 6 months run-in periods and
1-year follow up period) are employed in a NHI claims data-
bases. New migraineurs were identiﬁed on the basis of ICD-9-
CM codes, and direct treatment costs were calculated using
Taiwan NHI payments for migraine related medical events by
type of medical care. Data on the cost of outpatient care, med-
ications, and inpatient care were collected. Comorbid conditions
were based on the diagnostic classiﬁcations from the Charlson
comorbidity index. The log-transformed direct costs were ana-
lyzed by multivariate techniques. Control variables included
demographics, type of providers, comorbidities, and follow up
periods. RESULTS: Of 24,801 remained patients for study, there
are 21,924 (88.4%) migraine alone and 2,877 (11.6%) migraine
with comorbid conditions. The differences between migraine
with comorbid conditions and migraine alone in total mean costs
per patient were NTC2284 during the study period (NTC3737
vs. 1453; p < 0.001). Higher prescription drug costs of
NTC1521, higher physician visit costs of NTC581 accounted 
for most of the difference. The differences in total mean costs
per patient for migraine with comorbid conditions relative to
migraine alone patients were higher for the 8 most prevalent
comorbidities. Higher costs were attributable to higher pre-
scription drug and physician visit utilization. However, differ-
ences varied across conditions, ranging from NTC6759 in higher
costs for diabetes with chronic complications to NTC156 in
higher costs for myocardial infraction. CONCLUSIONS: These
results demonstrate costs differences were smaller for acute con-
ditions such as myocardial infraction compared with chronic dis-
eases among comorbid conditions for patients diagnosed with
migraine.
PNL8
TRIPTANS IN THE ACUTE TREATMENT OF MIGRAINE: COST-
EFFECTIVENESS ANALYSIS BASED ON NUMBER NEEDED TO
TREAT AND DOSES NEEDED TO TREAT
Dugar A, Healey PJ,Weis K
Pﬁzer Global Pharmaceuticals, Pﬁzer, Inc, New York, NY, USA
OBJECTIVE: To determine the cost-effectiveness of six triptans
in the acute treatment of migraine based on number needed to
treat (NNT) and doses needed to treat (DNT) derived from data
in a published meta-analysis combined with the wholesale acqui-
sition cost (WAC). METHODS: Efﬁcacy and recurrence data
were obtained from a meta-analysis of 53 randomized, double
blind, controlled (placebo or active comparator) trials of triptan
use in adult outpatients (Ferrari 2001). Triptans studied were:
almotriptan 12.5mg (A12.5), eletriptan 40mg (E40), naratrip-
tan 2.5mg (N2.5), rizatriptan 5mg and 10mg (R5 and R10),
sumatriptan 50mg and 100mg (S50 and S100) and zolmitriptan
2.5mg and 5mg (Z2.5 and Z5). Treatment success was measured
by sustained pain-free therapeutic gain (SPFTG), the percentage
of patients who were pain-free within 2h post-dose (placebo-
subtracted), with no headache recurrence or use of rescue med-
ication within 24h. SPFTG was calculated using the published 
2h pain-free and recurrence rates. The NNT and DNT to achieve
100 successfully treated patients were calculated; DNT were
divided by the WAC (AnalySource®, September 2003) to obtain
cost per successfully treated patient (CPSTP). RESULTS: E40
and R10 had the highest SPFTG (18% and 19%, respectively);
N2.5 (11%), S50 (13%) and R5 (13%) had the lowest. E40 and
N2.5 had the lowest recurrence rates (21% each); R5 (39%) and
R10 (37%) had the highest. E40 and R10 had the lowest DNT
(686 and 713, respectively); N2.5 (1094) and R5 (1040) had 
the highest. CPSTP was lowest for E40 ($86.69), then R10
($102.32), and was highest for N2.5 ($181.99) and R5
($149.18). CONCLUSIONS: E40 and R10 had the lowest DNT.
E40 was the most cost-effective triptan, followed by R10; N2.5
was the least cost-effective. Results are important for health care
decision-makers in the acute treatment of migraine.
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OBJECTIVES: Interferon beta-1a (Avonex®) is efﬁcacious in
delaying clinically deﬁnite multiple sclerosis (CDMS) following
a single demyelinating event (SDE). The purpose of this study
was to determine the cost-effectiveness of Avonex® compared 
to current treatment (CT) in delaying the onset of CDMS.
METHODS: A cost effectiveness analysis (CEA) was performed.
The outcome of interest was time spent in the pre-CDMS state,
termed monosymptomatic life years (MLY) gained. A Markov
model was developed with all transitional probabilities derived
from the literature. Costs were reported in 2002 Canadian
dollars. Costs and outcomes were discounted at 5%. A time
horizon of 12 years was applied. All uncertainties were tested
via univariate and multivariate sensitivity analyses. RESULTS:
From the Ministry of Health (MoH) perspective, the total
expected costs per patient were $173,000 and $108,000 for
Avonex® and CT, respectively. From the SOC perspective, the
total expected costs were $317,000 and $262,000, respectively.
Expected MLYs gained were 4.69 for Avonex® and 3.48 for CT.
The incremental cost of Avonex® per MLY gained was $53,110
from the MoH perspective and $44,789 from the SOC perspec-
tive. The model was sensitive to the probability of progressing
to CDMS and the analytical time horizon. CONCLUSION: Our
results suggest that Avonex® may be considered as a reasonably
cost-effective approach to treatment of patients experiencing a
SDE. In addition, the overall incremental cost-effectiveness
proﬁle of Avonex® improves if treatment is initiated in pre-
CDMS rather than waiting until CDMS.
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OBJECTIVE: To model the economic implications of screening
for neutralizing antibodies (NAbs) to interferon beta (IFNb) in
treatment of relapsing-remitting multiple sclerosis (RRMS).
There is considerable evidence that NAbs to IFNb can reduce its
clinical efﬁcacy. NAb incidence ranges from 28–47% with IFNb-
1b (Betaseron), 12–24% with IFNb-1a (Rebif), and 2–6% with
IFNb-1a (Avonex). Early identiﬁcation of Nab + patients may
improve cost-effectiveness of IFNb therapy. METHODS: A
Markov model was constructed to estimate and compare costs
and quality of life-related utility of IFNb therapy. Seven treat-
ment scenarios (Avonex, Betaseron, and Rebif, with and without
291Abstracts
NAb screening, and no therapy) were included in the model.
Data from pivotal clinical trials, US product labeling, and other
published sources were used to estimate disease progression,
relapse rates, treatment efﬁcacy (reductions in relative risk of
progression/relapse; effect of NAbs on efﬁcacy), adverse events,
therapy discontinuation/switching, costs, and patient utilities.
For each treatment scenario, incremental cost per QALY was
assessed relative to no therapy, and each screening scenario 
was compared to its corresponding “no screening” scenario.
RESULTS: Incremental cost per QALY (lifetime treatment; 3%
discounting) ranged from $75,300 (Avonex) to $135,900
(Betaseron). NAb screening resulted in 10-year cost savings of
US$5100 per patient (Rebif) and US$3000 (Betaseron), versus
US$800 additional cost for Avonex. CONCLUSIONS: Based on
higher occurrence of NAbs with Betaseron and Rebif, universal
NAb screening of patients treated with these agents improves
clinical effectiveness and is cost saving. However, NAb screen-
ing for Avonex-treated patients is cost additive due to Avonex’s
lower immunogenicity.
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HEALTH CARE COSTS FOR FLORIDA MEDICAID RECIPIENTS
WITH MULTIPLE SCLEROSIS
Boulanger L, Friedman M, Dixon D, Menzin J
Boston Health Economics, Inc, Waltham, MA, USA
OBJECTIVE: To assess health care costs among patients with
multiple sclerosis (MS) in the Florida Medicaid program.
METHODS: We employed a retrospective matched cohort
design using administrative claims data for Florida Medicaid
recipients. Patients were included if they had a diagnosis of MS
between July 1, 2001 and June 30, 2002, and were eligible for
Medicaid as of July 1, 2001. Those covered in capitated plans
or dually eligible for Medicare and Medicaid were excluded. The
comparison cohort consisted of MS-free patients matched on
age, gender, and race to the MS group. The excess cost of MS
(in 2002 US dollars) was estimated as the difference in mean
Medicaid payments between the MS group and matched con-
trols. Patients were followed for 12 months unless eligibility ter-
minated earlier. RESULTS: A total of 951 patients with MS met
cohort selection criteria, a prevalence rate of approximately 8
per 10,000 Medicaid eligibles. About one-third of these patients
were dispensed glatiramer acetate or beta-interferon. MS
patients and matched controls (n = 951) averaged 43 years of
age; 78% were female, and 61% were white. Both cohorts had
similar mean Charlson comorbidity scores and low mortality
rates (<3%). Compared to their matched controls, MS patients
were more likely to be hospitalized (33% vs. 20%, respectively),
use nursing home services (15% vs. 3%), or use home health
care services (37% vs. 11%). The annual per-patient excess cost
of MS was estimated to be $11,383 ($20,264 vs. $8,881 for
matched controls). Long-term care accounted for 44% of the
excess costs, followed by medications (28%), and hospitaliza-
tions (14%). CONCLUSIONS: Although MS is relatively rare in
this Medicaid population, the per-patient costs are high. Long-
term care costs are the largest portion of Medicaid payments,
highlighting the disease burden.
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OBJECTIVES: Interferon beta-1a (Avonex®) is efﬁcacious in
delaying clinically deﬁnite multiple sclerosis (CDMS) following
a single demyelinating event (SDE). This study determined the
cost-utility of Avonex® compared to current treatment (CT) in
delaying the onset of CDMS. METHODS: A cost utility analy-
sis (CUA) was performed. The outcome of interest was the
quality adjusted time spent in the pre-CDMS state, termed
quality adjusted monosymptomatic life years (QAMLYs) gained.
A Markov model was developed with all transitional probabili-
ties and utilities derived from the literature. Costs were reported
in 2002 Canadian dollars. Costs and outcomes were discounted
at 5%. A time horizon of 15 years was applied. All uncertain-
ties were tested via univariate and multivariate sensitivity analy-
ses. RESULTS: From the Ministry of Health (MoH) perspective,
the total expected costs per patient over 15 years were $202,000
and $136,000 for Avonex® and CT, respectively. From the soci-
etal perspective, the total expected costs were $380,000 and
$327,000, respectively. Expected QAMLYs gained were 8.47 for
Avonex® and 8.18 for CT. The incremental cost of Avonex® per
QAMLY gained was $227,586 from the MoH perspective and
$189,286 from the societal perspective. The model was sensitive
to the probability of progressing to CDMS, the utilities, and the
analytical time horizon. CONCLUSION: This analysis demon-
strates an improvement in the cost utility of Avonex® compared
to a previously published CUA for CDMS, providing further evi-
dence of the beneﬁts of treatment following a SDE.
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A COMPARATIVE COST ANALYSIS OF VASCULAR DEMENTIA
VERSUS ALZHEIMER’S DISEASE IN TAIWAN
Lin CW, Lee CT
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OBJECTIVE: To compare the average direct costs for patients
diagnosed with vascular dementia (VaD) versus Alzheimer’s
disease (AD) from the perspective of the Taiwan National Health
Insurance (NHI) program. METHODS: Using health care claims
data for NHI recipients in the Bureau of National Health Insur-
ance Kao-Ping Branch, Taiwan, we evaluated NHI expenditures
among adults 50 + years of age diagnosed with VaD (ICD-9-CM
290.4X) or AD (ICD-9-CM 331.0) between July 1, 2000 and
December 31, 2002. Patient’s identiﬁcation period spanned from
Jan 1, 2001 through Dec 31, 2002 with a 6-month baseline
periods and 1-year follow up period. Direct costs estimated using
NHI physician fee schedules. Health care utilization and NHI
expenditures (in 2002 NHI reimbursement prices) were calcu-
lated overall and by component of care. Multivariate techniques,
based on regression analyses of the log of total costs, were
employed to adjust for differences between the study cohorts in
sociodemographics. RESULTS: In total, 1450 patients met study
inclusion criteria; Of the 710 were diagnosed with VaD, 41.6%
were women; Of the 740 with AD, 50.7% were women. The
average age for VaD was 76.25 years and 76.79 years for AD.
Relative to AD patients, the burden of comorbidity was higher
among VaD patients, especially for cerebrovascular disease
(43.2% vs. 15.9%), but also for diabetes (5.6% vs. 3.1%) and
chronic pulmonary disease (5.5% vs. 1.4%). Mean monthly
costs per patient were approximately NT$1013 higher for
patients with VaD versus AD (NT$5467 vs. 4454; p < 0.001).
Most of this excess cost were attributed to higher inpatient uti-
lization (84.8%) and mental health services (11.2%). Adjusting
for difference in age, gender, and comorbid conditions between
the two cohorts, mean monthly cost per patient were about
NT$1107 higher in the VaD cohort (NT$3892 vs. 2785; p <
0.001). CONCLUSIONS: Relative to AD patients, VaD have sig-
